79494-91-0

Upstream product

• 60656-87-3 benzyloxyacetoaldehyde 
• 245058-55-3 (5-benzyloxymethyl-tetrahydro-furan-2-ylmethyl)-dimethyl-phenyl-silane 
• 131830-52-9 1-O-Benzylhex-5-ene-1,2-diol 

Downstream Products

• 131729-45-8 5-<(hexadecyloxy)methyl>-2-<(benzyloxy)methyl>tetrahydrofuran 
• 114142-20-0 5-((benzyloxy)methyl)dihydrofuran-2(3H)-one 
• 431948-70-8 (5-oxotetrahydrofuran-2-yl)methyl benzoate 
• 107971-34-6 (tetrahydro-5-oxofuran-2-yl)methyl 4-methylbenzenesulfonate 

Relevant academic research and scientific papers

Synthesis of tetrahydrofurans by the reaction of α,β-epoxy alcohol derivatives with allylsilanes

In the presence of SnCl4, α,β-epoxy alcohol derivatives easily reacted with allylsilanes to give the corresponding tetrahydrofurans in moderate yields.

New 2,5-disubstituted tetrahydrofuran derivatives

The present invention relates to new derivatives of 2,5--disubstituted tetrahydrofurans with a potent antagonist activity of the platelet activating factor (PAF), together with a process for their preparation. The invention also relates to the pharmaceutical preparations which contain these compounds an their use in the treatment of diseases in which PAF is involved, such as allergic and bronchial asthma, platelet aggregation disorders, septic shock, hypertension, etc.

Disubstituted tetrahydrofurans and dioxolanes as PAF antagonists

A new series of disubstituted tetrahydrofuran and dioxolane derivatives were prepared and evaluated for their PAF antagonist activity in the PAF-induced in vitro platelet-aggregation and in vivo hypotension tests. Several of these compounds exhibited more potent activity than the structurally related 2-[N-acetyl-N-[[[[2-methoxy-3-[(octadecylcarbamoyl)oxy]propoxy] carbonyl]amino]methyl]-1-ethylpyridinium chloride (CV-6209, 3) in the in vitro assay, whereas all showed less potency in the in vivo test. The role of both the substituent nature and the placement and number of oxygen atoms in the ring are discussed. A qualitative SAR study was carried out on these nuclei.

Anti-arrhythmia agents

Acetamide derivatives are provided having the structure STR1 wherein X is a single bond, --CH2 -- or --O--, R1 and R2 may be the same or different and are lower alkyl, phenyl-lower alkoxy-lower alkyl, lower alkenyl, phenyl-lower alkyl or lower alkoxy, or STR2 may be taken together to form a 5- to 7-membered heterocyclic ring optionally containing one other hetero atom, such as nitrogen, sulfur or oxygen; Y is hydroxyl, OR wherein R is lower alkyl, lower alkenyl or lower alkanoyl, or STR3 wherein R1 and R2, and R1 and R2 taken together with the nitrogen to which they are attached are as defined above, and n is 1 to 6. These compounds are useful as anti-arrhythmia agents and have been found to be effective in the treatment of acute myocardial infarction.